Efruxifermin in non-alcoholic steatohepatitis: a randomized, double-blind, placebo-controlled, phase 2a trial

Therapeutic landscape for NAFLD in 2020

(2020) Brent A. Neuschwander-Tetri   GASTROENTEROLOGY

Efficacy and Safety of Aldafermin, an Engineered FGF19 Analog, in a Randomized, Double-Blind, Placebo-Controlled Trial of Patients With Nonalcoholic Steatohepatitis

(2020) Stephen A. Harrison et al.   GASTROENTEROLOGY

The therapeutic potential of FGF21 in metabolic diseases: from bench to clinic

(2020) Leiluo Geng et al.   Nature Reviews Endocrinology

FGF21: An Emerging Therapeutic Target for Non-Alcoholic Steatohepatitis and Related Metabolic Diseases

(2020) Erik J. Tillman et al.   Frontiers in Endocrinology

140-LB: NGM313, a Novel Activator of b-Klotho/FGFR1c, Improves Insulin Resistance and Reduces Hepatic Fat in Obese, Nondiabetic Subjects

(2019) ALEX DEPAOLI et al.   DIABETES

Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial

(2019) Stephen A Harrison et al.   LANCET

Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial

(2019) Zobair M Younossi et al.   LANCET

NGM282 for treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial

(2018) Stephen A Harrison et al.   LANCET

A Common Allele in FGF21 Associated with Sugar Intake Is Associated with Body Shape, Lower Total Body-Fat Percentage, and Higher Blood Pressure

(2018) Timothy M. Frayling et al.   Cell Reports

Pegbelfermin (BMS-986036), a PEGylated fibroblast growth factor 21 analogue, in patients with non-alcoholic steatohepatitis: a randomised, double-blind, placebo-controlled, phase 2a trial

(2018) Arun Sanyal et al.   LANCET

Pegbelfermin (BMS-986036), PEGylated FGF21, in Patients with Obesity and Type 2 Diabetes: Results from a Randomized Phase 2 Study

(2018) Edgar D. Charles et al.   Obesity

A Novel Fc-FGF21 With Improved Resistance to Proteolysis, Increased Affinity Toward β-Klotho, and Enhanced Efficacy in Mice and Cynomolgus Monkeys

(2017) Shanaka Stanislaus et al.   ENDOCRINOLOGY

The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases

(2017) Naga Chalasani et al.   HEPATOLOGY

A Long-Acting FGF21 Molecule, PF-05231023, Decreases Body Weight and Improves Lipid Profile in Non-human Primates and Type 2 Diabetic Subjects

(2016) Saswata Talukdar et al.   Cell Metabolism

Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes

(2016) Zobair M. Younossi et al.   HEPATOLOGY

Association of noninvasive quantitative decline in liver fat content on MRI with histologic response in nonalcoholic steatohepatitis

(2016) Janki Patel et al.   Therapeutic Advances in Gastroenterology

Weight Loss Through Lifestyle Modification Significantly Reduces Features of Nonalcoholic Steatohepatitis

(2015) Eduardo Vilar-Gomez et al.   GASTROENTEROLOGY

The Enhanced liver fibrosis score is associated with clinical outcomes and disease progression in patients with chronic liver disease

(2015) Katharine M. Irvine et al.   LIVER INTERNATIONAL

Markers of Collagen Remodeling Detect Clinically Significant Fibrosis in Chronic Hepatitis C Patients

(2015) Mette J. Nielsen et al.   PLoS One

Opposite alterations in FGF21 and FGF19 levels and disturbed expression of the receptor machinery for endocrine FGFs in obese patients

(2014) J M Gallego-Escuredo et al.   INTERNATIONAL JOURNAL OF OBESITY

The Effects of LY2405319, an FGF21 Analog, in Obese Human Subjects with Type 2 Diabetes

(2013) Gregory Gaich et al.   Cell Metabolism

Increased De Novo Lipogenesis Is a Distinct Characteristic of Individuals With Nonalcoholic Fatty Liver Disease

(2013) Jennifer E. Lambert et al.   GASTROENTEROLOGY

Uric Acid Induces Hepatic Steatosis by Generation of Mitochondrial Oxidative Stress

(2012) Miguel A. Lanaspa et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Adiponectin Regulation of Stellate Cell Activation via PPARγ-Dependent and -Independent Mechanisms

(2011) Mahnoush S. Shafiei et al.   AMERICAN JOURNAL OF PATHOLOGY

Prevalence of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis Among a Largely Middle-Aged Population Utilizing Ultrasound and Liver Biopsy: A Prospective Study

(2010) Christopher D. Williams et al.   GASTROENTEROLOGY

Association between serum uric acid level and chronic liver disease in the United States

(2010) Anita Afzali et al.   HEPATOLOGY

Fibroblast Growth Factor 21 Reverses Hepatic Steatosis, Increases Energy Expenditure, and Improves Insulin Sensitivity in Diet-Induced Obese Mice

(2008) J. Xu et al.   DIABETES